Dong-Mei Chen

Design, synthesis and biological evaluation of CYP1B1 targeted degraders for sensitizing immune checkpoint inhibitor therapy.

Despite its established role in tumor progression and therapy resistance, Cytochrome P450 1B1 (CYP1B1) has remained largely underexplored as a therapeutic target in immunotherapy, with no prior reports using CYP1B1-targeted agents to enhance immune checkpoint inhibitor efficacy. To address this, we designed a series of...